Document is current
Any future updates will be listed below
-
Authors
Shaaban, C. Elizabeth https://orcid.org/0000-0002-3016-1951
Suryadevara, Vidyani https://orcid.org/0000-0003-4081-2989
Hill, Ashley V.
Milani, Sadaf Arefi https://orcid.org/0000-0001-6631-6532
Agarwal, Puja https://orcid.org/0000-0002-0274-6653
Aggarwal, Neelum T.
Akinyemi, Rufus O.
Alladi, Suvarna
Brown, Monique J.
Caldwell, Jessica Z. K.
Caramelli, Paulo https://orcid.org/0000-0002-4786-6990
DuBose, Lyndsey
Ellajosyula, Ratnavalli
Esiaka, Darlingtina K.
Gibson, Allison
Griffith, Patrick
Harper, Joshua
Karanja, Wambūi
Li, Wei
Llibre-Guerra, Jorge J. https://orcid.org/0000-0002-2137-7750
Loi, Samantha M.
Mielke, Michelle M. https://orcid.org/0000-0001-7177-1185
Molina-Henry, Doris P.
Ogunniyi, Adesola
Pudumjee, Shehroo
Stites, Shana D.
Sundermann, Erin
Turner, Arlener D. https://orcid.org/0000-0002-0493-7736
Vila-Castelar, Clara
Viswanathan, Jayalakshmi https://orcid.org/0000-0001-5338-3170
Trani, Jean-François
Babulal, Ganesh M. https://orcid.org/0000-0001-7966-3509
,
,
- License Information
-
More Information
Article History
Received: 6 February 2024
Accepted: 4 November 2025
First Online: 21 January 2026
Competing interests
: J.Z.K.C. declares honoraria in the past 3 years from The Leon Thal Summit, The International Congress on the Future of Neurology, and Biogen. S.M.L. has received honoraria from Otsuka Lundbeck in the past 5 years. M.M.M. has served on scientific advisory boards and/or has consulted for Acadia, Althira, Biogen, Cognito Therapeutics, Eisai, Lilly, Merck, Novo Nordisk, Neurogen Biomarking, Roche, and Siemens Healthineers. The other authors declare no competing interests.
